ANI Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
ANI Pharmaceuticals's earnings have been declining at an average annual rate of -0.2%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 22.5% per year. ANI Pharmaceuticals's return on equity is 5.6%, and it has net margins of 4.3%.
Key information
-0.2%
Earnings growth rate
-1.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 22.5% |
| Return on equity | 5.6% |
| Net Margin | 4.3% |
| Next Earnings Update | 08 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ANI Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 539 | 23 | 184 | 39 |
| 31 Mar 24 | 517 | 31 | 173 | 39 |
| 31 Dec 23 | 487 | 15 | 162 | 34 |
| 30 Sep 23 | 449 | 10 | 150 | 30 |
| 30 Jun 23 | 401 | -8 | 129 | 26 |
| 31 Mar 23 | 359 | -28 | 122 | 23 |
| 31 Dec 22 | 316 | -50 | 115 | 22 |
| 30 Sep 22 | 283 | -69 | 112 | 20 |
| 30 Jun 22 | 251 | -65 | 99 | 15 |
| 31 Mar 22 | 226 | -63 | 86 | 14 |
| 31 Dec 21 | 216 | -43 | 84 | 11 |
| 30 Sep 21 | 212 | -22 | 61 | 12 |
| 30 Jun 21 | 213 | -17 | 66 | 16 |
| 31 Mar 21 | 213 | -15 | 62 | 13 |
| 31 Dec 20 | 208 | -23 | 65 | 16 |
| 30 Sep 20 | 199 | -24 | 65 | 17 |
| 30 Jun 20 | 198 | -20 | 57 | 15 |
| 31 Mar 20 | 203 | -1 | 56 | 19 |
| 31 Dec 19 | 207 | 6 | 56 | 20 |
| 30 Sep 19 | 216 | 16 | 55 | 18 |
| 30 Jun 19 | 215 | 17 | 53 | 17 |
| 31 Mar 19 | 208 | 14 | 48 | 18 |
| 31 Dec 18 | 202 | 15 | 44 | 15 |
| 30 Sep 18 | 192 | 0 | 40 | 13 |
| 30 Jun 18 | 189 | 0 | 36 | 11 |
| 31 Mar 18 | 187 | 0 | 33 | 10 |
| 31 Dec 17 | 177 | -1 | 32 | 9 |
| 30 Sep 17 | 168 | 7 | 30 | 7 |
| 30 Jun 17 | 158 | 5 | 29 | 5 |
| 31 Mar 17 | 145 | 4 | 28 | 4 |
| 31 Dec 16 | 129 | 4 | 27 | 3 |
| 30 Sep 16 | 108 | 8 | 25 | 3 |
| 30 Jun 16 | 90 | 10 | 23 | 3 |
| 31 Mar 16 | 78 | 12 | 22 | 3 |
| 31 Dec 15 | 76 | 15 | 21 | 3 |
| 30 Sep 15 | 79 | 33 | 20 | 3 |
| 30 Jun 15 | 77 | 35 | 19 | 3 |
| 31 Mar 15 | 64 | 30 | 18 | 3 |
| 31 Dec 14 | 56 | 29 | 17 | 3 |
| 30 Sep 14 | 45 | 11 | 15 | 3 |
| 30 Jun 14 | 36 | 5 | 14 | 2 |
| 31 Mar 14 | 35 | 1 | 12 | 2 |
| 31 Dec 13 | 30 | -5 | 11 | 2 |
Quality Earnings: BSFA has a large one-off gain of $8.9M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: BSFA became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BSFA has become profitable over the past 5 years, growing earnings by -0.2% per year.
Accelerating Growth: BSFA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BSFA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: BSFA's Return on Equity (5.6%) is considered low.